Latest Breaking News On - தொடர்புடையது தகவல் - Page 8 : comparemela.com

Merck Announces First-Quarter 2021 Financial Results First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40 … First-Quarter 2021 Sales Were $12.1 Billion, In-Line with First-Quarter 2020; Excluding the Impact from Foreign Exchange, Sales Declined 1% First-Quarter 2021 Sales Reflect Strong Underlying Performance of KEYTRUDA, Lynparza, BRIDION and Animal Health, Which Was Offset by COVID-19 Pandemic Impacts to Patient Access, Particularly for Vaccines First-Quarter 2021 GAAP EPS Was $1.25; First-Quarter Non-GAAP EPS Was $1.40

United statesPatrick ryanImplanon nexplanonCozaar hyzaarKennethc frazierRidgeback biotherapeuticsRobertm davisPeter dannenbaumPandion therapeutics incAmerican society for clinical oncologyMerck coAcquisition of pandion therapeutics incGilead sciences incStatement of merck co incMerck co incAnimal health revenue